Suppr超能文献

粪便微生物群移植治疗系统性硬化症的疗效和安全性:一项系统评价和荟萃分析方案

The efficacy and safety of fecal microbiota transplantation in the treatment of systemic sclerosis: A protocol for systematic review and meta analysis.

作者信息

Zhang Shixiong, Lv Jingjing, Ren Xuetong, Hao Xinyu, Zhou Pingping, Wang Yangang

机构信息

Hebei University of Chinese Medicine.

Hebei Province Hospital of Chinese Medicine, Shijiazhuang City, Hebei.

出版信息

Medicine (Baltimore). 2020 Jul 10;99(28):e21267. doi: 10.1097/MD.0000000000021267.

Abstract

BACKGROUND

Systemic sclerosis (SSc) is 1 of the most complex systemic autoimmune diseases.Accumulating evidence suggests that gut microbiota affect the development and function of the immune system and may play a role in the pathogenesis of autoimmune diseases. This new paradigm raises the possibility that many diseases result, at least partially, from microbiota-related dysfunction. This understanding invites the investigation of fecal microbiota transplantation (FMT) in the treatment of SSc. However, no study has specifically and systematically investigated the efficacy and safety of FMT in the treatment of SSc. Thus, this study will systematically and comprehensively appraise the efficacy and safety of FMT in the treatment of SSc.

METHODS

We will search the following sources without restrictions for date, language, or publication status: PubMed, Web of Science,Cochrane Central Register of Controlled Trials (CENTRAL) Cochrane Library, EMBASE and China National Knowledge Infrastructure. We will apply a combination of Medical Subject Heading (MeSH) and free-text terms incorporating database-specific controlled vocabularies and text words to implement search strategies. We will also search the ongoing trials registered in the World Health Organization's International Clinical Trials Registry Platform. Besides, the previous relevant reviews conducted on FMT for SSc and reference lists of included studies will also be searched.

RESULTS

This study will provide a reliable basis for the treatment of SSc with FMT.

CONCLUSIONS

The findings will be an available reference to evaluate the efficacy and safety of FMT in the treatment of SSc.

REGISTRATION NUMBER

INPLASY202060019.

摘要

背景

系统性硬化症(SSc)是最复杂的系统性自身免疫性疾病之一。越来越多的证据表明,肠道微生物群会影响免疫系统的发育和功能,并可能在自身免疫性疾病的发病机制中发挥作用。这种新的模式增加了许多疾病至少部分是由微生物群相关功能障碍导致的可能性。这种认识促使人们研究粪便微生物群移植(FMT)治疗SSc的效果。然而,尚无研究专门且系统地调查FMT治疗SSc的疗效和安全性。因此,本研究将系统、全面地评估FMT治疗SSc的疗效和安全性。

方法

我们将不受日期、语言或出版状态限制,检索以下来源:PubMed、科学网、Cochrane对照试验中心注册库(CENTRAL)、Cochrane图书馆、EMBASE和中国知网。我们将应用医学主题词(MeSH)和自由文本词相结合的方式,结合特定数据库的控制词汇和文本词来实施检索策略。我们还将检索世界卫生组织国际临床试验注册平台上正在进行的试验。此外,还将检索之前关于FMT治疗SSc的相关综述以及纳入研究的参考文献列表。

结果

本研究将为FMT治疗SSc提供可靠依据。

结论

这些发现将为评估FMT治疗SSc的疗效和安全性提供有用参考。

注册号

INPLASY202060019。

相似文献

本文引用的文献

9
Clinical Application and Potential of Fecal Microbiota Transplantation.粪便微生物移植的临床应用和潜力。
Annu Rev Med. 2019 Jan 27;70:335-351. doi: 10.1146/annurev-med-111717-122956. Epub 2018 Nov 7.
10
Systemic sclerosis: state of the art on clinical practice guidelines.系统性硬化症:临床实践指南的最新进展
RMD Open. 2018 Oct 18;4(Suppl 1):e000782. doi: 10.1136/rmdopen-2018-000782. eCollection 2018.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验